全文获取类型
收费全文 | 34616篇 |
免费 | 3128篇 |
国内免费 | 69篇 |
专业分类
耳鼻咽喉 | 303篇 |
儿科学 | 1217篇 |
妇产科学 | 1030篇 |
基础医学 | 4748篇 |
口腔科学 | 739篇 |
临床医学 | 4337篇 |
内科学 | 6241篇 |
皮肤病学 | 401篇 |
神经病学 | 3705篇 |
特种医学 | 759篇 |
外国民族医学 | 1篇 |
外科学 | 3898篇 |
综合类 | 578篇 |
一般理论 | 65篇 |
预防医学 | 4340篇 |
眼科学 | 726篇 |
药学 | 2379篇 |
中国医学 | 42篇 |
肿瘤学 | 2304篇 |
出版年
2023年 | 267篇 |
2022年 | 329篇 |
2021年 | 645篇 |
2020年 | 470篇 |
2019年 | 751篇 |
2018年 | 835篇 |
2017年 | 666篇 |
2016年 | 663篇 |
2015年 | 770篇 |
2014年 | 1061篇 |
2013年 | 1564篇 |
2012年 | 2194篇 |
2011年 | 2264篇 |
2010年 | 1282篇 |
2009年 | 1200篇 |
2008年 | 1937篇 |
2007年 | 2098篇 |
2006年 | 2035篇 |
2005年 | 1956篇 |
2004年 | 1961篇 |
2003年 | 1831篇 |
2002年 | 1685篇 |
2001年 | 554篇 |
2000年 | 521篇 |
1999年 | 508篇 |
1998年 | 388篇 |
1997年 | 356篇 |
1996年 | 263篇 |
1995年 | 255篇 |
1994年 | 203篇 |
1993年 | 246篇 |
1992年 | 332篇 |
1991年 | 325篇 |
1990年 | 327篇 |
1989年 | 298篇 |
1988年 | 268篇 |
1987年 | 225篇 |
1986年 | 275篇 |
1985年 | 239篇 |
1984年 | 214篇 |
1983年 | 233篇 |
1982年 | 198篇 |
1981年 | 176篇 |
1980年 | 201篇 |
1979年 | 208篇 |
1978年 | 182篇 |
1977年 | 176篇 |
1975年 | 169篇 |
1974年 | 183篇 |
1973年 | 190篇 |
排序方式: 共有10000条查询结果,搜索用时 24 毫秒
1.
2.
3.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
4.
5.
6.
7.
8.
9.
10.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献